Approximately 2.3% of adults will suffer from symptoms of Obsessive-Compulsive Disorder at some point in their life.
Exploring the companies and themes that make up this emerging and exciting new sector
Lobe Sciences Added to Horizons Psychedelic Stock Index ETF
Lobe Sciences becomes the latest addition to the Horizons psychedelics ETF (PSYK).
The First Psychedelic Medicine Clinic Opens in Minnesota
The growing rates of depression, anxiety, and other mental health illnesses have contributed to a national mental health crisis in the United States and call for new and unconventional treatment options.
Traumatic Brain Injury (TBI): Six Psychedelics Companies Target $120 Billion Market
One huge market. Six horses in the race (so far). Lots of prize money to go around.
Investing in Psychedelics with MindMed Stock
It was the late Robin Williams who once said, “Reality is just a crutch for people who can’t handle drugs.”
COMPASS Pathways granted two US patents
Compass is granted two psilocybin formulation patents, for treatment-resistant depression and major depressive disorder.
Psychedelic Drugs: The Miracle Drugs of the 21st Century
Are psychedelics "miracle drugs"? If we compare them to the first Miracle Drug, the answer seems to be "yes".
Top Psychedelic Penny Stocks To Watch After Latest Big Pharma Deal
Psychedelic Penny Stocks Continue Gaining Ground Among Mainstream Investors
MindMed Announces Inclusion in FTSE Russell Indexes
MindMed has been added to the FTSE Global Micro-Cap Index and the FTSE Total-Cap Index.
Andrew Yang Urges Legalization Of Psilocybin And Marijuana At New York City Mayoral Forum
Andrew Yang, a former 2020 Democratic presidential candidate who is now running for mayor of New York City, said in a recent campaign forum that he supports legalizing psilocybin and marijuana.
Red Light Holland Closes Acquisition of SR Wholesale Becoming a Leader in Distribution of Psychedelics
Red Light Holland acquires a Netherlands distributor of psilocybin-based products.
Numinus Announces Closing of $40-Million Bought Deal Financing
Numinus closes on a CAD$40.25 million bought deal financing, upsized from the original CAD$30 million offering.